Diachrome® Can Improve Insulin Sensitivity

BATON ROUGE, La.Taken in conjunction with oral anti-diabetic agents, chromium picolinate (CrPic) may improve insulin sensitivity and glucose control in people with type 2 diabetes better than an oral anti-diabetic agent alone. According to a study published in Diabetes Care (8:1826-32, 2006), CrPic supplementation significantly attenuates body weight gain and visceral fat accumulation.

Thirty-seven subjects with type 2 diabetes were evaluated. After baseline, subjects were placed on a sulfonylurea (5 mg/d) with placebo for three months. Subjects were then randomized in a double blind fashion to receive the sulfonylurea plus placebo or the sulfonylurea plus 1,000 mg/d of chromium as CrPic (as Diachrome®, from Nutrition 21) for six months. Body composition, insulin sensitivity and glycemic control were determined at baseline, at end of the three-month single-blind placebo phase and at the end of the study. CrPic supplementation in the participants with type 2 diabetes who took sulfonylurea agents significantly improved insulin sensitivity and glucose control. Also, CrPic supplementation significantly attenuated body weight gain and visceral fat accumulation.

According to Burcham Fuqua, M.D., the lead investigator of past clinical trials, Diachrome has been clinically demonstrated to improve blood sugar control, enhance the bodys response to insulin, and improve lipid parameters. These changes should translate into numerous health benefits including improved cardiovascular health.